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Serum cystatin C measured by automated immunoassay: A more
sensitive marker of changes in GFR than serum creatinine. Serum
cystatin C has been suggested as a new marker of GFR. For the
introduction of this marker into clinical use a rapid and automated
method is required. We have developed and validated an assay for serum
cystatin C using latex particle-enhanced immunoturbidimetty. Intra- and
inter-assay precision were < 3% and < 5% across the assay range.
Analytical recovery was 93 3.8% and no lack of parallelism was
demonstrated. Regression analysis of a method comparison with an
enzyme-enhanced radial-immunodiffusion method, gave PETIA = 0.074
+ 0.93 X SRID, r = 0.98, N = 100. Inter-assay precision profiles showed
cystatin C was measured with two-fold better precision than creatinine on
the same analyzer. Cystatin C measurement was neither interfered with by
icterus nor by hemolysis. 1/cystatin C versus 1/creatinine concentrations
gave r = 0.67, N = 469. Comparison of Cr EDTA GFR with 1/cystatin C
and 1/creatinine gave r = 0.81 and 0.50, respectively, N = 206. Calculating
diagnostic sensitivity for abnormal GFR showed cystatin C to be signifi-
cantly (P < 0.05) more sensitive than creatinine (71.4 vs. 52.4%). Cystatin
C measurement using PETIA technology can be automated on the same
instruments used routinely for the measurement of creatinine and offers
better analytical performance and probably improved clinical sensitivity as
a screening test for early renal damage.
Cystatin C is a non-glycosylated 13 kD basic protein that is a
member of the cystatin superfamily of cysteine protease inhibitors
[1—3]. It is produced by all nucleated cells and its production rate
is unaltered in inflammatory conditions [4, 5]. The structure of the
cystatin C gene and its promoter has been determined and the
gene seems to be of the housekeeping type, which is compatible
with a stable production rate of cystatin C by most cells [6]. The
low molecular weight of cystatin C in combination with its stable
production rate strongly indicates that the blood serum concen-
tration of this protein is mainly determined by the glomerular
filtration rate of the individual. There have been several papers
during recent years suggesting that cystatin C measurement in
serum correlates with glomerular filtration rate (GFR) [4, 5, 7].
Several other low molecular weight proteins, /32-microglobulin,
retinol binding protein and cs1-microglobulin (protein HC), have
been investigated for their utility in monitoring GFR [5, 8]. None
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of these have proven useful, due mainly to the influence of
non-renal factors on their circulating concentrations. The hypoth-
esis is that low molecular weight proteins are freely filtered at the
glomerulus and then either reabsorbed and metabolized or ex-
creted into the urine. The end result is that they are cleared from
the circulation and the circulating serum concentration will reflect
GFR if the production rate remains constant. The difficulty with
the aforementioned low molecular weight proteins is that the
production rate may vary due to infection, dietary factors and liver
disease [5, 7]. Creatinine and urea, which are more commonly
used for the clinical assessment of GFR, also have a range of
non-renal factors influencing their production, for example, mus-
cle mass and protein intake, and for creatinine there are several
well-reported difficulties concerning the analytical measurement
[9, 10]. There is thus a need to provide an alternative to creatinine
that is analytically more reliable and as or more clinically reliable.
Recent investigations have confirmed that the serum concen-
tration of cystatin C is at least as good an indicator of glomerular
filtration rate as the serum concentration of creatinine [4, 5, 7].
Although the numbers of samples have been small, there has also
been evidence that intercurrent infection and malignancy do not
affect circulating cystatin C concentrations. However, in these
studies the serum concentrations of cystatin C were determined by
enzyme amplified single radial immunodiffusion (SRID). Al-
though this method is analytically accurate and reasonably pre-
cise, it is slow, and does not permit automation and is therefore
far from ideal for clinical use. Other groups have developed
methods for cystatin C using ELISA [11—14], which although
enabling a greater output is still not amenable to routine analysis
on the scale of routine creatinine measurement. The present work
was undertaken in an effort to produce a rapid and automated
procedure for the quantitation of serum cystatin C based upon the
latex particle enhanced immunoturbidimetric assay (PETIA)
technique [15—17].
Methods
All reagents were analar grade (BDH, Poole, UK) unless
otherwise stated. Antiserum (Code No: A451) was a gift from
Dakopatts, Denmark; purified recombinant cystatin C for calibra-
tion was prepared according to Abrahamson et al [18]. Latex
particles, 77 nm in diameter (Bangs Laboratories, Indianapolis,
IN, USA) were covalently coupled to rabbit anti-human cystatin C
immunoglobulin fraction using a chloro-methyl styrene coupling
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chemistry [16]. Antibody was dialyzed into 15 m phosphate
buffer pH 7.4 and reacted overnight at 37°C in 15 m phosphate
buffer pH 7.4 containing 0.05% GAFAC RE61O (GAFc0, Wythen-
shaw, Manchester, UK). After coupling, particles were centri-
fuged at 50,000 g, the supernatant removed, followed by washing
with 50 m'vi glycine buffer pH 7.4 containing 0.05% GAFAC. This
procedure was repeated four times and then the washed particles
were resuspended in half the coupling volume of 500 mivi glycine
pH 7.4 containing 0.05% GAFAC. The reagent was then treated
on ice with 2 X 60 seconds of ultrasonication at 20 KHz (MSE
Soniprep, Crawley, Sussex, UK) to disrupt any aggregates and
stored at 4°C.
Experimental procedures
All analyses were performed on a Monarch 2000 centrifugal
analyzer (Instrumentation Laboratory, Warrington UK) operat-
ing at 37°C and monitoring at 340 nm in a disposable cuvette rotor
with a path length of 0.74 cm.
Assay optimization
All experiments were performed using solutions of purified
recombinant cystatin C prepared in horse serum (Sigma, Poole,
Dorset, UK) over a concentration range of 0 to 10 mg/liter. The
effect of reaction conditions on serum based nonspecific aggrega-
tion reactions was assessed at all stages. Antibody coated particles
were prepared with different protein loadings (0.5 to 3 mg of
antibody/mi particles) and at different particle concentrations (1
to 3% solids) and their functional immunoreactivity assessed at a
range of pH (pH 6 to 8), polyethylene glycol (molecular wt 6 to
8000, 0 to 2%), and salt concentrations [15]. The influence of
sample volume on the reaction kinetics and calibration curve was
also assessed. Horse serum (Sigma) and cystatin C free human
serum (prepared by affinity adsorption using an anti-cystatin C
antibody coupled solid-phase) were both evaluated for use as a
calibration matrix.
Assay validation
Analytical recovery and parallelism. Using the optimized assay
protocol analytical recovery was assessed in ten different serum
samples at two cystatin C concentrations (2.5 and 5.0 mg/liter).
Ten serum samples with high creatinine concentrations were
diluted in horse serum to assess parallelism.
Imprecision. The intra-assay precision was assessed using 20
replicate analyses of three serum pools at approximately 1, 3 and
8 mg/liter. Inter-assay precision was assessed in two ways: by
analyzing the aforementioned serum pools across twenty working
days, and by establishing a precision profile from analyzing 206
samples on two separate occasions. The same samples were used
to develop a precision profile for serum creatinine measurement
using a Jaffe method (Instrumentation Laboratories).
Method comparison and interferences. A total of 100 patient
samples was assayed for cystatin C using the method described
and the enzyme-enhanced radial immunodiffusion procedure [5];
a common calibrator was employed in both methods. Potential
interferences by rheumatoid factor was assessed by assay of 20
samples with elevated RF titers in both the proposed and SRID
methods. The potential interference of bilirubin, hemoglobin and
lipemia were assessed by performing analytical recovery experi-
ments in increasing concentrations of interferents; bilirubin (Sig-
ma) up to 700 tM, hemoglobin (human hemolysate) up to 1.0
g/liter, and triglyceride (Intralipid, Kabi Vitrum Ltd., Uxbridge,
UK) up to 40 m'vi equivalent triglyceride concentration.
Plasma versus serum. The effect of anticoagulants and clotting
was assessed by collecting blood (N = 10) into plain, heparin and
EDTA vacutainer tubes. The appropriate serum and plasma
fractions were assayed for cystatin C.
Sample stability. The effects of incomplete clotting and storage
of serum samples were evaluated by collecting five samples from
normal individuals and handling them in the following ways: (a)
allowed to clot for one hour, separated and analyzed immediately;
(b) allowed to clot for one hour then separated and stored at 4°C
overnight before analysis, or (c) at —20°C before analysis; (d)
stored on the clot overnight at 4°C before separation and analysis.
Clinical evaluation
Serum samples were obtained from 206 patients mainly from
the Departments of Nephrology, Rheumatology and Urology at
the University Hospital of Lund, Sweden. These included cases of
chronic glomerulonephritis, chronic pyelonephritis, amyloidosis
and post-operative assessments following surgery of the kidney
and urinary tract. GFR measurements had been made on these
patients according to the single injection technique using chromi-
um-EDTA complex (Cr51; Behringwerke AG, Marburg, Ger-
many) following the method of Brochner-Mortensen [19] as
modified by Brauner and Westling [20]. All GFR measurements
were performed at 7.30 a.m. with the subjects fasting. These
patients studied were selected on the basis of having a serum
creatinine of less than 300 imol/liter in order to study more
intensively the moderate changes in GFR. Over the period of this
study 263 random samples were also obtained from the Clinical
Biochemistry Laboratory at the Royal London Hospital. All these
samples were analyzed for serum cystatin C (PETIA) and creat-
mine (Jaffe method; Instrumentation Laboratories).
Statistical procedures
Regression analyses were performed using the Minitab Statis-
tical Package (Minitab Inc. PA, USA) and the method of Deming
[21]. Additional statistical analyses, Mann-Whitney U test, paired
and unpaired t-tests were performed using Statview® Abacus
Concepts Inc. (Berkeley, CA, USA) for Macintosh computers.
Clinical sensitivity and specificity was calculated according to
Galen and Gambino [22], with statistical comparison using an
unpaired t-test.
Results
The antibody particle reagent synthesis was optimized at 0.5 mg
antibody/mi of 1% particles. Nonspecific aggregation was minimal
with an appropriate specific absorbance change at a reaction pH
of 7.5, in a 340 m sodium phosphate buffer containing 10 g/liter
BSA and 1 g/liter sodium azide. The final assay protocol is shown
in Table 1, and typical calibration curves are shown in Figure 1 for
both calibration matrices.
Analytical recovery and parallelism were demonstrated; mean
serum recovery was 93 3.8%. intra- and inter-assay precision
was less than 3 and 5%, respectively, and for the serum assay
between 1.0 and 10 mg/liter, whether measured using quality
assessment pools or using the precision profile (Table 2 and Fig.
2). The precision profile for the Jaffe creatinine method is also
shown in Figure 2. The detection limit (2.5 SD from the zero
calibrator) for the serum cystatin C assay was 0.027 mg/liter.
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Initial read seconds 5
Read time seconds 300
The assay buffer was 340 mrvi sodium phosphate pH 7.5, containing 10
g/Iiter BSA and 1 g/liter sodium azide.
Antibody/particle was 0.5 mg antibody/mi 1% particles diluted to a
starting absorbance of approximately 0.7 (0.74 cm path length).
800
Cystatin C, mg/liter
Fig. 1. Calibration curves for the cystatin C PETIA in both horse semm (•)
and cystatin C free human sensm ([I]). This figure shows a hook effect at


























Analyte as multiples of value at GFR=72 mI/mm/i .73 m2
Fig. 2. Inter-assay precision profiles for sewm cystatin C () and creatinine(0), both assayed on the Monarch 2000 automated analyzer, N = 206.
Analyte concentrations on the abscissa have been normalized against their
respective values at a GFR of 72 ml/min/1.73 m2.
SRID, mg/liter
Fig. 3. Methods comparison between the cystatin C PETIA and an enzyme-
enhanced SRID assay. Deming regression analysis gave PETIA = 0.074 +
0.93 X SRID, N 100, r = 0.98.
Regression analysis (Deming) of the method comparison gave
PETIA = 0.074 + 0.93 X SRID, r = 0.98 (Fig. 3). There was no
interference from rheumatoid factor, bilirubin or hemolysis, but
triglycerides at concentrations greater than 10 mmol/liter caused a
reduced recovery of cystatin C. Both heparin and EDTA caused a
significant under-recovery of cystatin C (mean 27.3 and 52.6% of
serum concentrations, respectively). There was no significant
difference (paired t-test, P > 0.05) between samples analyzed
immediately versus those separated and stored at —20°C or 4°C,
or left unseparated on the clot overnight.
The relationship between reciprocal serum concentrations of
creatinine and cystatin C gave a regression analysis of 1/cystatin C































Table 2. Assay precision for the PETIA method
U
.
0 2 4 6 8
= 0.14 + 73.4 X 1/creatinine, r = 0.67, N = 469 (Fig. 4B). The
relationship between cystatin C concentrations and GFR is shown
in Figure 5, showing the classical curvilinear relationship demon-
strated by serum creatinine. Both cystatin C and creatinine
relationships with GFR are linearized by plotting their reciprocals
as shown in Figure 6 A and B; Deming regression analyses gave
1/cystatin C = 0.265 + 0.008 x GFR, r 0.81, and 1/creatinine =
0.0062 + 0.000062 x GFR, r = 0.50, N = 206 in both cases.
Taking a lower limit of the GFR reference range to be 72
ml/min/1.73 m2 [23], the sensitivity, specificity, predictive value of
positive and negative plus diagnostic efficiency were calculated for
both cystatin C and creatinine. The results are shown in Table 3.
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Fig. 5. Relationship between serum cystatin C and Cr ED TA GFR measure-
men4 N = 206. Shaded area shows where both parameters are within their
respective reference limits; dotted lines show upper or lower reference
limits. Sample 1 is from a renal transplant recipient, following several
rejection episodes, and on steroid and full immunosuppression therapy,
plus antihypertensive therapy. Sample 2 is from a patient with systemic
sclerosis and muscle wasting whose serum creatinine was 65 j.tmollliter.
Sample 3 is from a patient with severe rheumatoid arthritis and muscle
wasting whose serum creatinine was 67 tmol/liter.
Discussion
Fig. 4. Relationshz between serum creatinine and cystatin C concentrations,N = 469. Shaded area shows where both parameters are within their
respective reference limi , dotted lines show upper or lower reference limits.
(a) direct relationship and (b) reciprocal relationship. Deming regression
analysis gave 1/cystatin C = 0.14 + 73.4 X 1/creatinine, r = 0.67.
These data are expressed in a different way in Figure 7; the
measured cystatin C and creatinine concentrations are binned
into different GFR ranges, and the mean concentrations in each
bin are divided by the concentration of the analyte at a GFR of 72
ml/min/1.73 m2, thus expressing the data as multiples of their
respective concentrations at the lower limit of the GFR reference
range (mean SD). Serum cystatin C rose significantly earlier and
to a greater extent than serum creatinine as the GFR fell
(unpaired t-test).
The PETIA assay was optimized with an antibody loading of 0.5
mglml of 1% particles; this does not represent a saturated particle
surface with regards to total protein loading, but represents an
optimal immunoreactivity. Using the conventional validation pro-
cedures for analytical recovery and parallelism the accuracy of the
PETIA was demonstrated in serum. The SRID assay was deemed
to be a more reliable reference method than the EIA, both
published by one of us (AOG). A good correlation was observed
between the two methods further confirming the accuracy of the
PETIA even in the presence of rheumatoid factor. Figure 1 shows
a maximum signal change at about 10 mg/liter, and any sample
greater than this should be assayed after dilution with horse
serum. The extended calibration curve is included to demonstrate
that the highest concentrations of cystatin C found pathologically
(12 to 15 mg/liter) will give values of greater than 8 mg/liter when
assayed without pre-dilution. The security range for this assay is
thus very good and no false-low (that is, normal) concentrations
will be reported in end-stage renal failure.
No significant interferences were observed, although drug
interferences have not yet been assessed. Heparin and EDTA
plasma showed significantly different cystatin C concentrations to
serum. We would thus recommend that serum is the matrix of
choice for cystatin C analysis. The nature of these differences is
not clear, but may be charge-related in that the EDTA will
complex divalent cations which can play a role in promoting


















316 Newman et al: Cystatin C marker of GFR










URL 1.25 71.4a 95.1 90.9 82.9 85.4
mg/liter
URL = 1.50 50.0 98.4 95.5 74.1 78.6
mg/liter
Creatinine (Jaffe)
URL 110 52.4a 91.8 81.5 73.4 75.3
iimol/liter
URL = 120 39.3 97.5 91.7 70.0 73.8
pinol/liter
Assuming the lower reference limit for GFR = 72 ml/min/1.73 m2.
Healthy = GFR >72, N = 122. Disease = GFR <72, N = 84. URL =
upper reference limit of analyte; two concentrations have been used for
the URL of each analyte in order to compare sensitivities and specificities
at different cut off levels.
a Significantly different (unpaired t-test), P < 0.05
Fig. 6. Relationship between reciprocal Concentrations of cystatin C (A) and
creatinine (B) with Cr EDTA GFR, N = 206. Shaded area shows where
both parameters are within their respective reference limits, dotted lines
show upper or lower reference limits. Deming regression analyses gave
1/cystatin C = 0.265 + 0.008 x GFR, r = 0.81, and 1/creatinine = 0.0062
+ 0.000062 X GFR, r = 0.50.
immunoaggreagation reactions; the effect of the negatively-
charged heparin molecules is more difficult to explain as the latex
particles carry a net negative charge themselves.
The precision profile for the cystatin C PETIA shows a two- to
threefold better precision than that achieved for the creatinine
assay. This is particularly important at the upper limits of their
respective reference ranges (1.25 mg/liter for cystatin C and 110
mol/liter for creatinine). PETIA technology is not influenced by
icterus or hemolysis, both of which cause interference in creati-













Fig. 7. Proportional changes in cystatin C (•) and creatinine (A) normal-
ized using their respective concentrations at 72 mi/mm/i. 73 m2 GFR. The
error bars show the standard deviations for the distribution of results in
each GFR grouping. Statistical analyses used an unpaired t-test, cystatin C
vs. creatinine *p < 0.05, < 0.01; cystatin C or creatinine vs. values at
72 ml/min/1.73 m2 GFR, °P < 0.05, °°P < 0.01. This illustrates the earlier
and greater proportional rise in cystatin C concentrations as GFR
decreases.
analytical performance than serum creatinine measurement on a
routine automated clinical chemistry analyzer. The cost of a
PETIA assay is currently about the same as an enzymatic creati-
nine measurement, that is, about two to three times as expensive
as using the Jaffe based methodologies, as used here. The cost is
therefore not unreasonable and could possibly be reduced further
by replacement of the polyclonal antibody with a monoclonal
antibody whereby the economies of scale, in reagent production,
might be increased. The technology has been shown to be
extremely robust with calibration stabilities in excess of one year
[15—17]. PETIA technology can be applied to all clinical analyzers
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offers an appropriate technological approach if the clinical appli-
cability of cystatin C measurement can be confirmed.
Serum cystatin C concentrations measured by PETIA agree
well with those previously reported [4, 5, 7], and show a similar
relationship with creatinine concentration and 51Cr EDTA GFR.
The high creatinine sample (sample 1) in Figure 4A had a repeat
estimation of creatinine and a confirmation of the cystatin C
concentration on dilution and by SRID analysis; no explanation
for this discrepancy has been identified as yet. The proportional
rise in cystatin C concentrations is much greater than that for
creatinine, around the lower limit of the GFR reference range,
and the rate of relative increase appears to rise as the GFR falls
well below normal. The relationship with creatinine concentration
was not described in the previous studies [4, 5].
The reciprocal relationships between cystatin C and creatinine
with GFR show that the slope of the regression line is much
steeper with cystatin C (approximately twice as steep if the
concentration units are normalized) than for creatinine. There is
a much tighter distribution of results around the regression line
for cystatin C as indicated by the better correlation coefficient r =
0.81 versus 0.50 for creatinine. This compares with previously
published correlation coefficients for cystatin C of 0.77 and 0.75
[4, 5]. These studies involved 135 and 106 Cr EDTA GFR
comparisons. Therefore, in nearly 500 GFR studies serum cystatin
C measurement has been shown overall to be a reliable reflector
of GFR.
The clinical sensitivity of serum cystatin C measurement as a
predictor of GFR has not been previously calculated. Our data
show that, with either of the two upper reference concentrations
for the two analytes, cystatin C offers the greater sensitivity in
detecting an abnormal GFR, with equivalent specificity and
overall better diagnostic efficiency. This greater sensitivity is also
reflected by the expression of the data in Figure 7, where cystatin
C concentrations can be seen to rise more rapidly than those of
creatinine. Both cystatin C and creatinine show good specificities
for detecting an abnormal GFR. The poor sensitivity of creatinine
may be due to analytical or pathophysiological factors, and in the
former case analytical imprecision and interference could be
important. In the second instance the variety of non-renal influ-
ences on the circulating creatinine concentration result in a wide
reference range for creatinine; thus, GFR can change consider-
ably before creatinine becomes abnormal. The non-renal influ-
ences upon the circulating cystatin C concentration are less well
studied. It is known that there are age-related changes that
parallel known age-related changes in GFR [241.
Until very recently the available data suggested that serum
cystatin C concentrations were independent of gender [4, 5, 24];
however, the recent work of Pergande and Jung suggested that the
serum cystatin C concentrations were lower in women than men
[14]. Analysis of the data described in our study on the basis of sex
shows that, in two populations with a roughly equal spread in age
and GFR (Fig. 8), the mean female cystatin C concentration was
1.17 mg/liter and that of the male population 1.24 mg/liter. The
mean male concentration was 6% higher than the mean female
for cystatin C (not statistically significantly different, Mann-
Whitney U test), but for creatinine the difference was 17% (P <
0.05), suggesting that male/female differences are significantly
greater for creatinine. The difference between our studies and
those of Pergande and Jung are as yet unexplained. Their ELISA
used the same commercial source of antibody as this work but a
Fig. 8. Distribution of age, GFR cystatin C and creatinine in male (N =
115) and female (N = 91) subjects. Statistical analyses with the Mann-
Whitney U-test, P > 0.05 considered not significant. Symbols are: (LI)
male; ( ) female.
different calibrator material, and the latter is important as they
report significantly higher serum concentrations than other re-
ports (including our own). Additionally, there is no confirmatory
evidence that their reference populations had normal GFRs. A
full reference range study using a reference GFR procedure to
confirm a normal GFR needs to be performed; this could explore
the influences of sex, age, body mass. Further work is also
necessary to evaluate the response of cystatin C concentration to
the different renal replacement modalities. Further prospective
studies are required to monitor individual patients with different
renal pathologies, for example, diabetic nephropathy.
In summary, we have developed a fully automated assay for
serum cystatin C allowing the extensive clinical evaluation of this
new biochemical marker of GFR. Using PETIA technology, we
have produced an assay that is applicable to all clinical analyzers
used for the measurement of creatinine. Serum cystatin C has
been shown to be in all likelihood a more sensitive marker of early
deterioration in GFR than serum creatinine.
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